Trial Type: Gastrointestinal

UMI22-09-02
Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
BH-P-CEDER
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair
Protocol Status: OPEN TO ACCRUAL
Contact: Carneiro, Benedito
BRUOG-430
A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
SWOGS2205
Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
Protocol Status: OPEN TO ACCRUAL
Contact: Graff, Stephanie
LS-P-HEAT
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Birnbaum, Ariel
BH-P-SPARK
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
BH-P-LAMP
A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS5361b in Participants With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Carneiro, Benedito
BH-P-ENACT
A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
LS-P-CAPE
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
Protocol Status: OPEN TO ACCRUAL
Trial Type: Gastrointestinal
Contact: Raufi, Alexander
LS-P-IMPACT
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
Protocol Status: OPEN TO ACCRUAL
Contact: Carneiro, Benedito